Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2074205062', 'doi': 'https://doi.org/10.1179/102453310x12583347010133', 'title': 'Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)', 'display_name': 'Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)', 'publication_year': 2010, 'publication_date': '2010-04-01', 'ids': {'openalex': 'https://openalex.org/W2074205062', 'doi': 'https://doi.org/10.1179/102453310x12583347010133', 'mag': '2074205062', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/20423566'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1179/102453310x12583347010133', 'pdf_url': 'https://www.tandfonline.com/doi/pdf/10.1179/102453310X12583347010133?needAccess=true&role=button', 'source': {'id': 'https://openalex.org/S195061619', 'display_name': 'Hematology', 'issn_l': '1024-5332', 'issn': ['1024-5332', '1027-7501', '1607-8454'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320442', 'host_organization_name': 'Maney Publishing', 'host_organization_lineage': ['https://openalex.org/P4310320442'], 'host_organization_lineage_names': ['Maney Publishing'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': True, 'oa_status': 'bronze', 'oa_url': 'https://www.tandfonline.com/doi/pdf/10.1179/102453310X12583347010133?needAccess=true&role=button', 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5027513506', 'display_name': 'M. Wang', 'orcid': 'https://orcid.org/0009-0000-9433-392X'}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'M. Wang', 'raw_affiliation_strings': ['Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.'], 'affiliations': [{'raw_affiliation_string': 'Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.', 'institution_ids': ['https://openalex.org/I1343551460']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5047673513', 'display_name': 'Kay Delasalle', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'K. Delasalle', 'raw_affiliation_strings': ['Department of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA'], 'affiliations': [{'raw_affiliation_string': 'Department of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA', 'institution_ids': ['https://openalex.org/I1343551460']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5070096873', 'display_name': 'Sergio Giralt', 'orcid': 'https://orcid.org/0000-0003-1944-5053'}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'S. Giralt', 'raw_affiliation_strings': ['Department of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA'], 'affiliations': [{'raw_affiliation_string': 'Department of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA', 'institution_ids': ['https://openalex.org/I1343551460']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5007796652', 'display_name': 'Raymond Alexanian', 'orcid': 'https://orcid.org/0000-0002-3030-7404'}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'R. Alexanian', 'raw_affiliation_strings': ['Department of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030-4009, USA. [email protected]'], 'affiliations': [{'raw_affiliation_string': 'Department of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030-4009, USA. [email protected]', 'institution_ids': ['https://openalex.org/I1343551460']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': {'value': 2085, 'currency': 'GBP', 'value_usd': 2557, 'provenance': 'doaj'}, 'apc_paid': None, 'fwci': 2.41, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 21, 'citation_normalized_percentile': {'value': 0.725921, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 89, 'max': 90}, 'biblio': {'volume': '15', 'issue': '2', 'first_page': '70', 'last_page': '73'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10649', 'display_name': 'Multiple Myeloma Research and Treatments', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10649', 'display_name': 'Multiple Myeloma Research and Treatments', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12534', 'display_name': 'Protein Degradation and Inhibitors', 'score': 0.9989, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T10952', 'display_name': 'PI3K/AKT/mTOR signaling in cancer', 'score': 0.9906, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/melphalan', 'display_name': 'Melphalan', 'score': 0.74592453}], 'concepts': [{'id': 'https://openalex.org/C2776063141', 'wikidata': 'https://www.wikidata.org/wiki/Q425681', 'display_name': 'Lenalidomide', 'level': 3, 'score': 0.9084276}, {'id': 'https://openalex.org/C2780401358', 'wikidata': 'https://www.wikidata.org/wiki/Q422252', 'display_name': 'Dexamethasone', 'level': 2, 'score': 0.899892}, {'id': 'https://openalex.org/C2779609412', 'wikidata': 'https://www.wikidata.org/wiki/Q203174', 'display_name': 'Thalidomide', 'level': 3, 'score': 0.8533013}, {'id': 'https://openalex.org/C2776364478', 'wikidata': 'https://www.wikidata.org/wiki/Q467635', 'display_name': 'Multiple myeloma', 'level': 2, 'score': 0.83249426}, {'id': 'https://openalex.org/C2777478702', 'wikidata': 'https://www.wikidata.org/wiki/Q419319', 'display_name': 'Bortezomib', 'level': 3, 'score': 0.8085891}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.8046162}, {'id': 'https://openalex.org/C2778684742', 'wikidata': 'https://www.wikidata.org/wiki/Q2298283', 'display_name': 'Melphalan', 'level': 3, 'score': 0.74592453}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.54017234}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.38024372}, {'id': 'https://openalex.org/C90924648', 'wikidata': 'https://www.wikidata.org/wiki/Q120569', 'display_name': 'Gastroenterology', 'level': 1, 'score': 0.37310863}], 'mesh': [{'descriptor_ui': 'D000971', 'descriptor_name': 'Antineoplastic Combined Chemotherapy Protocols', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D009101', 'descriptor_name': 'Multiple Myeloma', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D000328', 'descriptor_name': 'Adult', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000368', 'descriptor_name': 'Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000369', 'descriptor_name': 'Aged, 80 and over', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000971', 'descriptor_name': 'Antineoplastic Combined Chemotherapy Protocols', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000971', 'descriptor_name': 'Antineoplastic Combined Chemotherapy Protocols', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D001897', 'descriptor_name': 'Boronic Acids', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D001897', 'descriptor_name': 'Boronic Acids', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001897', 'descriptor_name': 'Boronic Acids', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D000069286', 'descriptor_name': 'Bortezomib', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D003131', 'descriptor_name': 'Combined Modality Therapy', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D003907', 'descriptor_name': 'Dexamethasone', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D003907', 'descriptor_name': 'Dexamethasone', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D003907', 'descriptor_name': 'Dexamethasone', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D004341', 'descriptor_name': 'Drug Evaluation', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D005260', 'descriptor_name': 'Female', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006402', 'descriptor_name': 'Hematologic Diseases', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006402', 'descriptor_name': 'Hematologic Diseases', 'qualifier_ui': 'Q000139', 'qualifier_name': 'chemically induced', 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000077269', 'descriptor_name': 'Lenalidomide', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008297', 'descriptor_name': 'Male', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008558', 'descriptor_name': 'Melphalan', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008558', 'descriptor_name': 'Melphalan', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D008875', 'descriptor_name': 'Middle Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009101', 'descriptor_name': 'Multiple Myeloma', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009101', 'descriptor_name': 'Multiple Myeloma', 'qualifier_ui': 'Q000601', 'qualifier_name': 'surgery', 'is_major_topic': False}, {'descriptor_ui': 'D009422', 'descriptor_name': 'Nervous System Diseases', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009422', 'descriptor_name': 'Nervous System Diseases', 'qualifier_ui': 'Q000139', 'qualifier_name': 'chemically induced', 'is_major_topic': False}, {'descriptor_ui': 'D036102', 'descriptor_name': 'Peripheral Blood Stem Cell Transplantation', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011719', 'descriptor_name': 'Pyrazines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011719', 'descriptor_name': 'Pyrazines', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D011719', 'descriptor_name': 'Pyrazines', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D012074', 'descriptor_name': 'Remission Induction', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D012189', 'descriptor_name': 'Retrospective Studies', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013792', 'descriptor_name': 'Thalidomide', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013792', 'descriptor_name': 'Thalidomide', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D013792', 'descriptor_name': 'Thalidomide', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D013792', 'descriptor_name': 'Thalidomide', 'qualifier_ui': 'Q000031', 'qualifier_name': 'analogs & derivatives', 'is_major_topic': False}, {'descriptor_ui': 'D013997', 'descriptor_name': 'Time Factors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014182', 'descriptor_name': 'Transplantation, Autologous', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.1179/102453310x12583347010133', 'pdf_url': 'https://www.tandfonline.com/doi/pdf/10.1179/102453310X12583347010133?needAccess=true&role=button', 'source': {'id': 'https://openalex.org/S195061619', 'display_name': 'Hematology', 'issn_l': '1024-5332', 'issn': ['1024-5332', '1027-7501', '1607-8454'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320442', 'host_organization_name': 'Maney Publishing', 'host_organization_lineage': ['https://openalex.org/P4310320442'], 'host_organization_lineage_names': ['Maney Publishing'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/20423566', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1179/102453310x12583347010133', 'pdf_url': 'https://www.tandfonline.com/doi/pdf/10.1179/102453310X12583347010133?needAccess=true&role=button', 'source': {'id': 'https://openalex.org/S195061619', 'display_name': 'Hematology', 'issn_l': '1024-5332', 'issn': ['1024-5332', '1027-7501', '1607-8454'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320442', 'host_organization_name': 'Maney Publishing', 'host_organization_lineage': ['https://openalex.org/P4310320442'], 'host_organization_lineage_names': ['Maney Publishing'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'score': 0.82, 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 25, 'referenced_works': ['https://openalex.org/W1964991829', 'https://openalex.org/W1967381972', 'https://openalex.org/W1970074537', 'https://openalex.org/W1978377409', 'https://openalex.org/W1992538067', 'https://openalex.org/W2008182609', 'https://openalex.org/W2017303578', 'https://openalex.org/W2021954218', 'https://openalex.org/W2059733579', 'https://openalex.org/W2078115159', 'https://openalex.org/W2083107653', 'https://openalex.org/W2102591890', 'https://openalex.org/W2108235071', 'https://openalex.org/W2113101033', 'https://openalex.org/W2120161314', 'https://openalex.org/W2120474651', 'https://openalex.org/W2132242107', 'https://openalex.org/W2133986577', 'https://openalex.org/W2144531125', 'https://openalex.org/W2150254829', 'https://openalex.org/W2168929741', 'https://openalex.org/W2169336006', 'https://openalex.org/W2321655863', 'https://openalex.org/W2333363976', 'https://openalex.org/W3145716452'], 'related_works': ['https://openalex.org/W3042537788', 'https://openalex.org/W2979889274', 'https://openalex.org/W2462844398', 'https://openalex.org/W2362389383', 'https://openalex.org/W2118465399', 'https://openalex.org/W2058009067', 'https://openalex.org/W2041042375', 'https://openalex.org/W2022036807', 'https://openalex.org/W1980068016', 'https://openalex.org/W1974135782'], 'abstract_inverted_index': {'Between': [0], 'April': [1], '2006': [2], 'and': [3, 33, 46, 123], 'June': [4], '2009,': [5], '34': [6], 'newly': [7, 143], 'diagnosed': [8, 144], 'patients': [9, 57, 80, 145], 'with': [10, 84, 117, 125, 146], 'multiple': [11, 147], 'myeloma': [12], 'received': [13, 81], 'one': [14, 133], 'to': [15, 60, 105, 115], 'three': [16], 'courses': [17, 136], 'of': [18, 53, 63, 70, 76, 98, 108, 129], 'bortezomib': [19], '1.3': [20], 'mg/m(2)': [21, 36], 'i.v.': [22], 'four': [23], 'times,': [24], 'lenalidomide': [25], '25': [26], 'mg': [27], 'p.o.': [28, 37], 'daily': [29], 'for': [30, 38, 132, 142], '21': [31], 'days': [32, 40, 43], 'dexamethasone': [34], '20': [35], '4': [39], 'beginning': [41], 'on': [42], '1,': [44], '9': [45], '17': [47], '(BLD).': [48], 'There': [49], 'was': [50, 102, 137], 'rapid': [51], 'onset': [52], 'remission': [54, 100], 'in': [55], '30': [56], '(88%)': [58], 'similar': [59, 104], 'the': [61, 95, 106], 'frequency': [62, 97, 107], '87%': [64], 'induced': [65], 'by': [66, 88], 'a': [67, 74], 'previous': [68, 118], 'combination': [69, 128], 'bortezomib-thalidomide-dexamethasone': [71], '(BTD).': [72], 'After': [73], 'median': [75], '3.6': [77], 'months,': [78], '28': [79], 'intensive': [82], 'therapy': [83], 'high-dose': [85], 'melphalan': [86], 'supported': [87], 'autologous': [89], 'blood': [90], 'stem': [91], 'cells,': [92], 'so': [93], 'that': [94], 'overall': [96], 'complete': [99], '(CR)': [101], '44%,': [103], '37%': [109], 'observed': [110], 'previously.': [111], 'Side': [112], 'effects': [113], 'due': [114], 'thalidomide': [116], 'BTD': [119], 'were': [120], 'less': [121], 'frequent': [122], 'severe': [124], 'BLD.': [126], 'The': [127], 'BLD': [130], 'given': [131], 'or': [134], 'two': [135], 'an': [138], 'effective': [139], 'primary': [140], 'treatment': [141], 'myeloma.': [148]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2074205062', 'counts_by_year': [{'year': 2017, 'cited_by_count': 1}, {'year': 2015, 'cited_by_count': 2}, {'year': 2014, 'cited_by_count': 2}, {'year': 2013, 'cited_by_count': 2}, {'year': 2012, 'cited_by_count': 8}], 'updated_date': '2024-12-08T10:45:16.169490', 'created_date': '2016-06-24'}